MCID: LYM118
MIFTS: 70

Lymphoma

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Lymphoma

Summaries for Lymphoma

MedlinePlus : 43 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to follicular lymphoma and follicular lymphoma 1. An important gene associated with Lymphoma is TCL6 (T Cell Leukemia/Lymphoma 6
In the course of characterizing the TML1 gene, we further identified a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus.
Dysfunction Pattern: ), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1491)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 35.2 BCL10 BCL2 BCL6 CCND1 MYC
2 follicular lymphoma 1 35.1 BCL10 BCL2 BCL6
3 primary effusion lymphoma 35.0 BCL6 MYC TCL1A
4 peripheral t-cell lymphoma 35.0 ALK BCL6 TCL1A
5 diffuse large b-cell lymphoma 35.0 ALK BCL10 BCL6 MALT1 MYC
6 lymphoma, mucosa-associated lymphoid type 34.9 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
7 gastric lymphoma 34.9 BAX BCL10 BCL2 BCL6
8 nodular lymphocyte predominant hodgkin lymphoma 34.8 BCL6 CCND1
9 lymphoma, small cleaved-cell, diffuse 34.7 BCL2 CCND1
10 marginal zone b-cell lymphoma 34.7 BCL10 BCL2 BCL6 MALT1
11 nodal marginal zone b-cell lymphoma 34.6 BCL2 BCL6 MALT1
12 primary cutaneous marginal zone b-cell lymphoma 34.6 BCL10 MALT1
13 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 34.5 BCL6 CXCR5
14 alk-negative anaplastic large cell lymphoma 34.5 ALK BAX BCL2
15 lymphoma, hodgkin, classic 34.5 ALK BCL6 PVT1
16 diffuse large b-cell lymphoma of the central nervous system 34.5 BCL2 MYC
17 lung lymphoma 34.5 ALK BCL6 MALT1
18 breast lymphoma 34.4 ALK BCL6
19 intravascular large b-cell lymphoma 34.4 BCL2 BCL6
20 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.1 BCL2 BCL6 MYC
21 primary mediastinal large b-cell lymphoma 34.0 BCL2 BCL6
22 lymphoma, non-hodgkin, familial 33.9 ALK ATM BAX BCL10 BCL2 BCL6
23 mantle cell lymphoma 33.8 ATM BCL2 BCL6 CCND1 GAS5 MALT1
24 burkitt lymphoma 33.7 BAX BCL2 BCL6 BCL7A CXCR5 MYC
25 precursor t-cell acute lymphoblastic leukemia 33.2 BAX BCL10 MYC TCL1A
26 b-cell lymphomas 32.4 BAX BCL10 BCL2 BCL6 CCND1 GAS5
27 leukemia, chronic lymphocytic 31.5 ATM BAX BCL10 BCL2 BCL6 CCND1
28 t-cell leukemia 31.2 BCL11B GAS5 MYC TCL1A TCL6
29 prolymphocytic leukemia 31.1 ATM CCND1 MYC TCL1A
30 t-cell prolymphocytic leukemia 30.9 ATM MYC TCL1A
31 gastric adenocarcinoma 30.8 BAX BCL2 CCND1 MYC
32 suppressor of tumorigenicity 3 30.3 BAX BCL2 MYC
33 li-fraumeni syndrome 30.3 ATM BAX BCL2
34 myeloma, multiple 30.1 CCND1 GAS5 MYC PVT1
35 acute promyelocytic leukemia 29.5 BAX BCL2 MYC PVT1
36 nasopharyngeal carcinoma 29.3 BCL2 CCND1 GAS5 MYC PVT1
37 glioma 29.3 BAX BCL2 CCND1 GAS5 PVT1
38 cervical cancer 28.8 BAX CCND1 GAS5 MYC PVT1
39 ovarian cancer 28.7 ATM BAX BCL2 CCND1 GAS5 MYC
40 esophageal cancer 28.3 BAX CCND1 GAS5 MYC PVT1
41 gastric cancer 27.8 CCND1 GAS5 MYC PVT1 SNHG5
42 bladder urothelial carcinoma 27.6 CCND1 GAS5 PVT1
43 bladder cancer 27.5 CCND1 GAS5 MYC PVT1 SNHG5
44 colorectal cancer 26.8 ATM BAX BCL10 BCL2 CCND1 GAS5
45 prostate cancer 26.6 BAX BCL2 CCND1 GAS5 MYC PVT1
46 primary central nervous system lymphoma 12.4
47 anaplastic large cell lymphoma 12.4
48 plasmablastic lymphoma 12.3
49 extranodal nasal nk/t cell lymphoma 12.3
50 gray zone lymphoma 12.3

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

GenomeRNAi Phenotypes related to Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 ATM BAX BCL10 BCL2 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 ATM BAX BCL10 BCL2 CCND1 MALT1

MGI Mouse Phenotypes related to Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 BAX BCL10 CCND1 CXCR5 BCL11A BCL11B
2 endocrine/exocrine gland MP:0005379 10.02 BCL10 CCND1 BCL11A BCL11B ALK BCL2
3 hematopoietic system MP:0005397 10 BCL10 CCND1 CXCR5 BCL11A MALT1 BCL11B
4 immune system MP:0005387 9.9 BCL10 CCND1 CXCR5 BCL11A MALT1 BCL11B
5 mortality/aging MP:0010768 9.73 BCL6 BCL7A BAX BCL10 CCND1 BCL11A
6 neoplasm MP:0002006 9.23 CCND1 BCL11B MYC ALK BCL2 ATM

Drugs & Therapeutics for Lymphoma

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
6
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
7
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
8
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
9
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
10
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
11
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
14
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
15
Neumega 18 OPRELVEKIN Genetics Institute November 1997
16
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
17
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
18
Targretin 18 49 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
UVADEX 18 METHOXSALEN Therakos February 1999
21
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
23
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
24
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
25
Zydelig 18 49 IDELALISIB Gilead July 2014
26
Zykadia 18 49 CERITINIB Novartis April 2014
27
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 962)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
4
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
8
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
9
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
11
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
12
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 151165 6918365
13
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 172673-20-0 219090
14
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
15
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
16
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
17
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
19
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
20
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
21
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
22
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
23
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
24
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
27
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
28
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
29
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
30
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
31
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
32
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
33
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
34
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
35
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
36
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
37
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 298-81-7 4114
38
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
39
Granisetron Approved, Investigational Phase 4,Phase 2,Not Applicable 109889-09-0 3510
40
Palonosetron Approved, Investigational Phase 4,Phase 2,Not Applicable 135729-61-2, 119904-90-4, 135729-56-5 148211
41
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
42
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
43
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
44
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
46
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
47
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
48
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
49
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
50
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212

Interventional clinical trials:

(show top 50) (show all 6502)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
6 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
12 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
13 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
14 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
15 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
16 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
17 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
18 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
19 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
20 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
21 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
22 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
23 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
24 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
25 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
26 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
27 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
28 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
29 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
30 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
31 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
32 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
33 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
34 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
35 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
36 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
37 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
38 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
39 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
40 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
41 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
42 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
43 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
44 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
45 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
46 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
47 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
48 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
49 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
50 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lung, Myeloid, Thyroid

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 26199)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. ( 29805746 )
2018
3
MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma. ( 29559342 )
2018
4
Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. ( 29662618 )
2018
5
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
6
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
7
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. ( 29442161 )
2018
8
Plasmablastic lymphoma presenting as a ureteral polypoid mass. ( 29692511 )
2018
9
Intestinal Perforation Due to Crohn's Ileitis Immunosuppression Related Lymphoma and Meckel's Diverticulum. ( 29730434 )
2018
10
Management of radiation-induced valvular heart disease due to Hodgkin's Lymphoma in the modern era. ( 29131805 )
2018
11
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. ( 29923173 )
2018
12
A Case of Extranodal Metastasis of Primary Bone Lymphoma in the Lower Extremity. ( 29547041 )
2018
13
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. ( 29674443 )
2018
14
An unusual presentation of primary pulmonary extranodal marginal zone lymphoma of mucosal associated lymphoid tissue: An autopsy case report. ( 29452080 )
2018
15
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. ( 29978458 )
2018
16
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
17
Radiation therapy in primary testicular lymphoma: does practice match the standard of care? ( 29966467 )
2018
18
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review. ( 29719812 )
2018
19
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
20
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
21
Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-I^t in peripheral T-cell lymphoma, not otherwise specified. ( 29775622 )
2018
22
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. ( 29774105 )
2018
23
Adult-onset hydroa vacciniforme-like lymphoma in a long-term resident of the United States. ( 29693057 )
2018
24
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. ( 29845599 )
2018
25
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA). ( 29963527 )
2018
26
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
27
Primary Cutaneous Follicle Center Lymphoma Clear Cell Variant: Expanding the Spectrum of Cutaneous Clear Cell Neoplasms. ( 29877892 )
2018
28
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. ( 29978498 )
2018
29
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. ( 29679112 )
2018
30
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )
2018
31
Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. ( 28744882 )
2018
32
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. ( 29898619 )
2018
33
Primary jejunal Burkitt lymphoma in a child: ultrasonic detection. ( 29770187 )
2018
34
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
35
The B cell receptor signaling pathway in mantle cell lymphoma. ( 29861875 )
2018
36
Clinical management and outcomes of completely resected stage I follicular lymphoma. ( 29415976 )
2018
37
Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. ( 29721249 )
2018
38
Hydroa Vacciniforme-Like Cutaneous T-Cell Lymphoma in an Adult Presenting With Facial Edema and Recurrent Oral Ulceration. ( 29473835 )
2018
39
Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013). ( 29796994 )
2018
40
Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )
2018
41
JC Virus Granule Cell Neuronopathy and Lymphoma. ( 29977966 )
2018
42
Ulcerated necrobiosis lipoidica: A cutaneous granulomatous reaction associated with systemic B-cell lymphoma. ( 29770790 )
2018
43
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma? ( 29452668 )
2018
44
Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas ( 29801398 )
2018
45
Primary central nervous system vasculitis associated with lymphoma. ( 29429967 )
2018
46
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( 29193018 )
2018
47
Orthodeoxia as a presentation of intravascular large B cell lymphoma. ( 29796279 )
2018
48
Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation. ( 29963513 )
2018
49
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. ( 29332711 )
2018
50
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction. ( 29766398 )
2018